Success in the US for NZX-listed cancer diagnostics company Pacific Edge has lead to record revenues in the current half year, and a reduced loss margin.
The company has recently had its bladder cancer tests approved for American Medicare and Medicaid patients, which fed into a 50%
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
